Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer

Launched by CENTRE FRANCOIS BACLESSE · Aug 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a special approach to supportive care can help women who have completed treatment for gynecological cancers, specifically ovarian and endometrial cancer. The aim is to see if providing personalized support in a day hospital setting, along with a coordinated follow-up, makes a difference in the quality of life for these patients compared to standard care. Participants will be divided into two groups: one will receive this personalized care plan in a day hospital, while the other will receive the same plan but without the day hospital visits.

To join the study, participants must be women over 18 who are in remission after their first treatment for ovarian or endometrial cancer. They should also be fluent in French, have a phone for communication, and be covered by a social security plan. Those who might not be eligible include individuals with certain health conditions that could affect their participation or those currently facing a cancer recurrence. Throughout the trial, participants can expect regular follow-ups and support to help improve their recovery and overall well-being.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient \> 18 years
• • Patients in remission from first-line treatment of endometrial or ovarian/tumor/peritoneal cancer.
• • Patient who has completed her initial treatment; patients on maintenance therapy are eligible.
• • Fluency in French
• • Patient with access to a telephone line
• • Patient affiliated to a social security scheme
• • Signature of informed consent prior to any specific study procedure
• Exclusion Criteria:
• • Any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study
• • Patient with locoregional or metastatic recurrence
• • Patient deprived of liberty, under guardianship or curatorship
• • Simultaneous participation in a therapeutic clinical trial